Track topics on Twitter Track topics that are important to you
ALPHARETTA, Ga., Aug. 11, 2015 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB:SNWV), today reported financial results for the three and six months ended June 30, 2015 and provided a business update. The Company will host a conference call tomorrow, Wednesday, August 12, 2015, at 10:00 a.m. Eastern Time.
Highlights of the second quarter and recent weeks:
"We have had a very busy second quarter, achieving many of the milestones we established on our last conference call," stated Kevin A. Richardson, II, Chairman of the board of SANUWAVE. "We extended the due date of our debt with HealthTronics, which will allow us the flexibility to complete our PMA submission. Our shareholders overwhelming approved an increase in authorized shares, which will allow us to raise adequate capital to move forward as a company. At the same time we are well aware of making sure we minimize dilution to our faithful shareholders. We also had an extremely positive meeting with the FDA in June and now feel confident that when our top line data is revealed, in early September, we will be in a position to successfully submit our PMA to the FDA. In addition, we expanded our patent portfolio and have seen a strong level of inbound interest in commercializing our patent portfolio."
"As we look at the remainder of 2015 we have three milestones which need to be met: 1) reveal top line data from the study, 2) begin submission of the PMA to the FDA, and 3) raise capital or complete a joint venture, partnership or sale of the wound product to complete the FDA trial successfully and begin commercialization of the product in 2016. We are also working on a number of other non-medical initiatives, which we will keep shareholders abreast of as they occur," concluded Mr. Richardson.
Second Quarter Financial Results
Revenues for the three months ended June 30, 2015 were $239,983, compared to $238,115 for the same period in 2014, an increase of $1,868, or 1%. The increase in revenues for 2015 was due to higher sales of orthoPACE devices.
Research and development expenses for the three months ended June 30, 2015 were $456,789, compared to $1,013,652 for the same period in 2014, a decrease of $556,863, or 55%. Research and development costs decreased in 2015 as a result of lower payments to third party clinical sites participating in the dermaPACE clinical study as there were fewer active patients in the clinical study as compared to the prior period.
General and administrative expenses for the three months ended June 30, 2015 were $636,570, as compared to $694,402 for the same period in 2014, a decrease of $57,832, or 8%. General and administrative expenses in 2014 included consulting costs related to the capital raises completed in March 2014. The lower consulting costs were partially offset by higher legal fees in 2015 related to patent filings.
Net loss for the three months ended June 30, 2015 was $1,521,533, or ($0.02) per share, compared to a net loss of $1,693,650, or ($0.03) per share, for the same period in 2014, a decrease in the net loss of $172,117, or 10%. The decrease in the net loss was primarily a result of reduced operating expenses in 2015 discussed above offset by the loss on the warrant valuation adjustment.
Six Months Ended June 30, 2015 Financial Results
Revenues for the six months ended June 30, 2015 were $450,435, compared to $383,213 for the same period in 2014, an increase of $67,222, or 18%. The increase in revenues for 2015 was due to higher sales of orthoPACE devices in Europe.
Research and development expenses for the six months ended June 30, 2015 were $1,091,412, compared to $1,778,497 for the same period in 2014, a decrease of $687,085, or 39%. Research and development costs decreased in 2015 as a result of lower payments to third party clinical sites participating in the dermaPACE clinical study as there were fewer active patients in the clinical study as compared to the prior period.
General and administrative expenses for the six months ended June 30, 2015 were $1,202,862, as compared to $1,994,713 for the same period in 2014, a decrease of $791,851, or 40%. General and administrative expenses in 2014 included consulting costs related to the capital raises completed in March 2014. The lower consulting costs were partially offset by higher legal fees in 2015 related to patent filings.
Net loss for the six months ended June 30, 2015 was $2,680,648, or ($0.04) per share, compared to a net loss of $4,257,604, or ($0.10) per share, for the same period in 2014, a decrease in the net loss of $1,576,956, or 37%. The decrease in the net loss was primarily a result of reduced operating expenses in 2015 discussed above.
On June 30, 2015, the Company had cash and cash equivalents of $1,615,727 compared with $3,547,071 as of December 31, 2014, a decrease of $1,931,344. For the six months ended June 30, 2015, net cash used by operating activities was $1,917,858, compared to $4,093,335 for the same period in 2014, a decrease of $2,175,477, or 53%. The decrease in cash used by operations was primarily due to the lower operating expenses in 2015 and the reduction of accounts payable and accrued expenses in 2014.
The Company will also host a conference call on Wednesday, August 12, 2015, beginning at 10 a.m. Eastern Time to discuss the second quarter financial results, provide a business update and answer questions. Shareholders and other interested parties can participate in the conference call by dialing 877-407-9055 (U.S. and Canada) or 201-493-6743 (international).
A replay of the conference call will be available beginning two hours after its completion through August 26, 2015, by dialing 877-660-6853 (U.S. and Canada) or 201-612-7415 (international) and entering Conference ID 414704.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE's portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body's normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA's Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets.
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
(FINANCIAL TABLES FOLLOW)
|SANUWAVE HEALTH, INC. AND SUBSIDIARIES|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|Cash and cash equivalents||$ 1,615,727||$ 3,547,071|
|Accounts receivable, net of allowance for doubtful accounts||48,508||86,404|
|TOTAL CURRENT ASSETS||2,077,829||4,033,896|
|PROPERTY AND EQUIPMENT, at cost, less accumulated depreciation||5,990||7,840|
|INTANGIBLE ASSETS, at cost, less accumulated amortization||460,135||613,513|
|TOTAL ASSETS||$ 2,555,240||$ 4,666,355|
|Accounts payable||$ 285,528||$ 231,840|
|Accrued employee compensation||127,809||2,226|
|Interest payable, related parties||80,968||81,864|
|Notes payable, related parties||--||5,372,743|
|TOTAL CURRENT LIABILITIES||1,414,007||6,217,755|
|Notes payable, related parties||5,336,705||--|
|COMMITMENTS AND CONTINGENCIES|
|PREFERRED STOCK, SERIES A CONVERTIBLE, par value $0.001, 6,175 authorized; 6,175 shares issued and 0 and 1,165 shares outstanding in 2015 and 2014, respectively||--||1|
|PREFERRED STOCK - UNDESIGNATED, par value $0.001, 4,993,825 shares authorized; no shares issued and outstanding||--||--|
|COMMON STOCK, par value $0.001, 150,000,000 shares authorized; 63,056,519 and 60,726,519 issued and outstanding in 2015 and 2014, respectively||63,057||60,727|
|ADDITIONAL PAID-IN CAPITAL||86,632,205||86,584,472|
|ACCUMULATED OTHER COMPREHENSIVE LOSS||(25,963)||(12,477)|
|TOTAL STOCKHOLDERS' DEFICIT||(4,195,472)||(1,551,400)|
|TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT||$ 2,555,240||$ 4,666,355|
|SANUWAVE HEALTH, INC. AND SUBSIDIARIES|
|CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS|
Three Months Ended
Three Months Ended
Six Months Ended
Six Months Ended
|REVENUES||$ 239,983||$ 238,115||$ 450,435||$ 383,213|
|COST OF REVENUES||75,779||63,399||134,597||81,736|
|Research and development||456,789||1,013,652||1,091,412||1,778,497|
|General and administrative||636,570||694,402||1,202,862||1,994,713|
|TOTAL OPERATING EXPENSES||1,170,973||1,789,513||2,449,502||3,936,073|
|Loss on warrant valuation adjustment||(429,311)||--||(373,285)||--|
|Interest expense, net||(81,636)||(77,838)||(160,980)||(620,130)|
|Loss on foreign currency exchange||(3,817)||(1,015)||(12,719)||(2,878)|
|TOTAL OTHER EXPENSE||(514,764)||(78,853)||(546,984)||(623,008)|
|LOSS BEFORE INCOME TAXES||(1,521,533)||(1,693,650)||(2,680,648)||(4,257,604)|
|INCOME TAX EXPENSE||--||--||--||--|
|OTHER COMPREHENSIVE LOSS|
|Foreign currency translation adjustments||(768)||(3,549)||(13,486)||(4,981)|
|TOTAL COMPREHENSIVE LOSS||$ (1,522,301)||$ (1,697,199)||$ (2,694,134)||$ (4,262,585)|
|LOSS PER SHARE:|
|Net loss - basic and diluted||$ (0.02)||$ (0.03)||$ (0.04)||$ (0.10)|
|Weighted average shares outstanding - basic and diluted||63,056,519||48,423,293||62,993,885||44,035,108|
|SANUWAVE HEALTH, INC. AND SUBSIDIARIES|
|CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS|
Six Months Ended
Six Months Ended
|CASH FLOWS FROM OPERATING ACTIVITIES|
|Net loss||$ (2,680,648)||$ (4,257,604)|
|Adjustments to reconcile loss from continuing operations to net cash used by operating activities|
|Change in allowance for doubtful accounts||(3,099)||151|
|Stock-based compensation - employees, directors and advisors||50,062||57,755|
|Loss on warrant valuation adjustment||373,285||--|
|Amortization of debt discount||951||--|
|Stock issued for consulting services||--||743,150|
|Accretion of interest on warrants issued concurrent with a convertible promissory note||--||339,864|
|Accrued interest on 18% Convertible Promissory Notes||--||7,168|
|Changes in assets - (increase)/decrease|
|Accounts receivable - trade||40,995||79,864|
|Changes in liabilities - increase/(decrease)|
|Accrued employee compensation||125,583||(14,722)|
|Interest payable, related parties||(896)||(82,761)|
|Promissory notes - accrued interest||--||(21,813)|
|NET CASH USED BY OPERATING ACTIVITIES||(1,917,858)||(4,093,335)|
|CASH FLOWS FROM INVESTING ACTIVITIES|
|Purchase of property and equipment||--||(3,436)|
|NET CASH USED BY INVESTING ACTIVITIES||--||(3,436)|
|CASH FLOWS FROM FINANCING ACTIVITIES|
|Proceeds from 2014 Private Placement, net||--||8,562,500|
|Proceeds from sale of capital stock - subscription agreement||--||900,000|
|Proceeds from 18% Convertible Promissory Notes||--||815,000|
|Proceeds from convertible promissory notes, net||--||325,000|
|Proceeds from employee stock option exercise||--||12,600|
|Payments of principal on convertible promissory notes||--||(450,000)|
|Payments of principal on promissory notes||--||(90,000)|
|Payments of principal on capital lease||--||(2,608)|
|NET CASH PROVIDED BY FINANCING ACTIVITIES||--||10,072,492|
|EFFECT OF EXCHANGE RATES ON CASH||(13,486)||(4,981)|
|NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS||(1,931,344)||5,970,740|
|CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD||3,547,071||182,315|
|CASH AND CASH EQUIVALENTS, END OF PERIOD||$ 1,615,727||$ 6,153,055|
|Cash paid for interest||$ 161,936||$ 244,836|
CONTACT: Todd Markey IR Partners 818-280-6800 firstname.lastname@example.org Daniel Conway DC Consulting, LLC 407-792-3333 email@example.com SANUWAVE Health, Inc. Kevin Richardson II Chairman of the Board 617-778-9223 firstname.lastname@example.orgNEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...